Creative Planning’s Ligand Pharmaceuticals LGND Stock Holding History

Creative Planning’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,603	Closed	-$99K	–	2030
2018 Q3	$99K	Buy	+1,603	New	+$242K	﹤0.01%	1793
2017 Q2	–	Sell	-1,603	Closed	-$1K	–	4730
2017 Q1	$1K	Buy	+1,603	New	+$105K	﹤0.01%	4460

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Creative Planning's LGND Position: Q2 2026 in Review

Creative Planning increased its Ligand Pharmaceuticals (LGND) stake by 17% in Q2 2026, buying an estimated $347K and bringing the position to 9,979 shares worth $3.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Creative Planning first reported a position in LGND in Q2 2013 and has held it in 35 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Creative Planning held 9,979 shares of Ligand Pharmaceuticals worth $3.15M as of Q2 2026.
Creative Planning bought 1,474 Ligand Pharmaceuticals shares in Q2 2026, an estimated $347K.
Ligand Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1742 holding.
Creative Planning first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.